Raptor Pharmaceutica (RPTP) 7.45 $RPTP
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) and Other Inhaled Antibiotics at the ERS International Congress
GlobeNewswire - Wed Aug 24, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the European Respiratory Society (ERS) International Congress 2016 and will present data from a systematic literature review and network meta-analysis comparing the efficacy of QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, with other inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis. The presentation will be at the European Respiratory Society (ERS) International Congress in London, United Kingdom, at London EXCEL from Saturday, September 3, to Wednesday, September 7, 2016.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Voted A "Best Places to Work" Company in the North San Francisco Bay Area
GlobeNewswire - Thu Aug 18, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11 Annual North Bay Business Journal competition. The results of the best places to work in the North Bay will be featured in the September 19, 2016 publication of the North Bay Business Journal.
RPTP: 7.45 (-0.22)
Raptor Pharmaceuticals (RPTP) in Focus: Stock Up 5.7%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:05AM CDT
Raptor Pharmaceuticals Corp. (RPTP) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
RPTP: 7.45 (-0.22)
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.44 (+0.01), SYN: 1.64 (unch), RPTP: 7.45 (-0.22), INCY: 81.10 (+0.12)
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:08PM CDT
Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million
RPTP: 7.45 (-0.22)
ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:54AM CDT
Investor focus will remain on the performance of ACADIA's (ACAD) recently launched Nuplazid.
ACAD: 32.13 (-0.41), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), XLRN: 30.01 (-0.31)
Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:18AM CDT
Our proven model does not conclusively show that Ligand (LGND) is likely to beat earnings estimates this quarter.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), LGND: 103.31 (-1.00), XLRN: 30.01 (-0.31)
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 234.54 (-2.45), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), TEVA: 50.39 (-0.17)
Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 5:49AM CDT
With no approved products in its portfolio, focus will remain on Juno's (JUNO) pipeline and cash burn.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), JUNO: 29.58 (-1.95), CELG: 106.74 (-0.28)
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GlobeNewswire - Thu Jul 28, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
GlobeNewswire - Fri Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIR to inhaled tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infections that were presented at the 39 European Cystic Fibrosis Conference in Basel, Switzerland.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) at European Cystic Fibrosis Conference
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:07PM CDT
PROCYSBI Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 7.45 (-0.22), EBIO: 4.88 (+0.15), PTCT: 8.21 (+0.52), PETX: 8.87 (-0.36), ARRY: 3.43 (-0.17)
Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 7.45 (-0.22)
Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 10:22AM CDT
Image source: Raptor Pharmaceuticals Corp. What: Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence . ...
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Launches QUINSAIR(TM) in Europe
GlobeNewswire - Mon Apr 11, 6:05AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR(TM) (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.
RPTP: 7.45 (-0.22)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 7.45 (-0.22), TTNP: 5.62 (+0.03), MNKD: 0.80 (+0.10), TLOG: 0.22 (unch)
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) and Other Inhaled Antibiotics at the ERS International Congress
GlobeNewswire - Wed Aug 24, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the European Respiratory Society (ERS) International Congress 2016 and will present data from a systematic literature review and network meta-analysis comparing the efficacy of QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, with other inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis. The presentation will be at the European Respiratory Society (ERS) International Congress in London, United Kingdom, at London EXCEL from Saturday, September 3, to Wednesday, September 7, 2016.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Voted A "Best Places to Work" Company in the North San Francisco Bay Area
GlobeNewswire - Thu Aug 18, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11 Annual North Bay Business Journal competition. The results of the best places to work in the North Bay will be featured in the September 19, 2016 publication of the North Bay Business Journal.
RPTP: 7.45 (-0.22)
Raptor Pharmaceuticals (RPTP) in Focus: Stock Up 5.7%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:05AM CDT
Raptor Pharmaceuticals Corp. (RPTP) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
RPTP: 7.45 (-0.22)
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.44 (+0.01), SYN: 1.64 (unch), RPTP: 7.45 (-0.22), INCY: 81.10 (+0.12)
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:08PM CDT
Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million
RPTP: 7.45 (-0.22)
ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:54AM CDT
Investor focus will remain on the performance of ACADIA's (ACAD) recently launched Nuplazid.
ACAD: 32.13 (-0.41), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), XLRN: 30.01 (-0.31)
Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:18AM CDT
Our proven model does not conclusively show that Ligand (LGND) is likely to beat earnings estimates this quarter.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), LGND: 103.31 (-1.00), XLRN: 30.01 (-0.31)
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 234.54 (-2.45), RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), TEVA: 50.39 (-0.17)
Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 5:49AM CDT
With no approved products in its portfolio, focus will remain on Juno's (JUNO) pipeline and cash burn.
RPTP: 7.45 (-0.22), TECH: 105.35 (+0.85), JUNO: 29.58 (-1.95), CELG: 106.74 (-0.28)
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GlobeNewswire - Thu Jul 28, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
GlobeNewswire - Fri Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIR to inhaled tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infections that were presented at the 39 European Cystic Fibrosis Conference in Basel, Switzerland.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) at European Cystic Fibrosis Conference
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:07PM CDT
PROCYSBI Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 7.45 (-0.22)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 7.45 (-0.22), EBIO: 4.88 (+0.15), PTCT: 8.21 (+0.52), PETX: 8.87 (-0.36), ARRY: 3.43 (-0.17)
Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 7.45 (-0.22)
Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 10:22AM CDT
Image source: Raptor Pharmaceuticals Corp. What: Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence . ...
RPTP: 7.45 (-0.22)
Raptor Pharmaceutical Launches QUINSAIR(TM) in Europe
GlobeNewswire - Mon Apr 11, 6:05AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR(TM) (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.
RPTP: 7.45 (-0.22)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 7.45 (-0.22), TTNP: 5.62 (+0.03), MNKD: 0.80 (+0.10), TLOG: 0.22 (unch)
